Cancer Research

Cancer cell therapy pioneer Carl June receives the Sanford Lorraine Cross Award

The Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center received the award for his work in developing chimeric antigen receptor (CAR) T cell therapy.

Steve Graff

The backlog in mammograms during the COVID-19 pandemic

The backlog of diagnostic mammograms is not expected to return to regular operations for nearly six months at best, and a lack of early detection will have health implications on cancer management for years to come.

From Penn LDI

Media Contact


In the News

CBS News

Cancer Moonshot project launched by President Biden 5 years ago leading to many breakthroughs

Robert Vonderheide of Penn’s Abramson Cancer Center in the Perelman School of Medicine spoke about the Cancer Moonshot project, which has led to major federal funding for cancer research and subsequently, new treatments for patients. “It’s new initiatives, new therapies, and new ways importantly to prevent cancer in the first place,” he said.


The Washington Post

For those at risk for cancer, weighing the risk of COVID-19 with delays in screening and treatment

Lawrence Shulman of the Perelman School of Medicine says declining numbers of new cancer diagnoses over the past four months don’t mean fewer people actually have cancer. “There are a lot of patients out there who have cancer but are not undergoing diagnosis and entry into the cancer care system,” he said.


New Scientist

CRISPR cancer trial finds that gene-edited immune cells are safe

Edward Stadtmauer and Carl June of the Perelman School of Medicine spoke about a clinical trial that found it safe to inject CRISPR gene-edited immune cells into people with advanced cancer.



Deciphering a cancer treatment’s dark side

Saar Gill of the Perelman School of Medicine said it would be easier to treat cancer using CAR-T cell therapy without the looming possibility of triggering cytokine release syndrome.


Scientific American

Could immunotherapy treat diseases besides cancer?

Jonathan Epstein of the Perelman School of Medicine is quoted on how immunotherapy has transformed cancer care.


Philadelphia Inquirer

The world’s first T-cell therapy for a solid tumor cancer is made in Philly

Carl June of the Perelman School of Medicine commented on news of Iovance Biotherapeutics’ new facilities in South Philadelphia. “Recent advances in the understanding of cancer and the immune system have made a compelling case that [tumor-infiltrating lymphocyte] therapy could be effective in diverse cancers beyond melanoma, such as lung cancer and cervical cancer,” he said. “The decision of Iovance to conduct commercial scale manufacturing in the Philadelphia Navy Yard is wonderful news.”